Pegfilgrastim

Last updated

Pegfilgrastim
Clinical data
Trade names Neulasta
Biosimilars pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, pegfilgrastim-pbbk, Armlupeg, [1] [2] Cegfila, [3] Filpegla, [4] Fulphila, [5] Fylnetra, [6] Grasustek, [7] Lapelga, Neutropeg, Niopeg, [8] Nyvepria, Pelgraz, Pelmeg, [9] Ristempa, Stimufend, [10] [11] Tezmota, [12] Udenyca, Ziextenzo [13] [14]
AHFS/Drugs.com Monograph
MedlinePlus a607058
License data
Pregnancy
category
Routes of
administration 		Subcutaneous
Drug class Hematopoietic agents, colony-stimulating factors, immunostimulants
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life 15–80 hrs
Identifiers
  • N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard 100.169.155 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C845H1343N223O243S9
Molar mass 18802.90 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. [19] It serves to stimulate the production of white blood cells (neutrophils). [19] [21] Pegfilgrastim was developed by Amgen. [22]

Contents

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. [23]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). [24] [23]

Pegfilgrastim was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002. [22] [20] [25] [26] [27] It is on the World Health Organization's List of Essential Medicines. [28]

Medical uses

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; and to increase survival in people acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome). [19] [29] [30]

Society and culture

In January 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dyrupeg, intended to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy. [31] The applicant for this medicinal product is CuraTeQ Biologics s.r.o. [31] Dyrupeg is a biosimilar medicinal product. [31] It is highly similar to the reference product Neulasta (pegfilgrastim), which was authorized in the EU in August 2002. [31]

References

  1. ↑ "Regulatory Decision Summary for Armlupeg". Drug and Health Products Portal. 16 August 2024. Retrieved 27 December 2024.
  2. ↑ "Summary Basis of Decision for Armlupeg". Drug and Health Products Portal. 22 December 2024. Retrieved 25 January 2025.
  3. 1 2 "Cegfila EPAR". European Medicines Agency (EMA). 20 December 2019. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  4. 1 2 3 "Filpegla | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  5. 1 2 "Fulphila EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  6. 1 2 "Fylnetra- pegfilgrastim injection". DailyMed. 26 May 2022. Archived from the original on 3 July 2022. Retrieved 19 June 2022.
  7. 1 2 "Grasustek EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  8. 1 2 "Summary Basis of Decision for Niopeg". Drug and Health Products Portal. 1 September 2012. Retrieved 17 December 2024.
  9. 1 2 "Pelmeg EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  10. 1 2 "Stimufend- pegflilgrastim-fpgk injection, solution". DailyMed. 15 September 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
  11. 1 2 "Stimufend EPAR". European Medicines Agency (EMA). 4 April 2022. Archived from the original on 21 April 2022. Retrieved 4 April 2022.
  12. ↑ "Tezmota". NPS MedicineWise. 15 July 2021. Archived from the original on 29 September 2022. Retrieved 19 February 2022.
  13. 1 2 "Ziextenzo EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  14. ↑ "Summary Basis of Decision (SBD) for Ziextenzo". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  15. 1 2 "Ziextenzo". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 20 October 2021. Retrieved 25 August 2020.
  16. ↑ "Pegfilgrastim Use During Pregnancy". Drugs.com. 9 December 2019. Archived from the original on 5 December 2020. Retrieved 13 July 2020.
  17. ↑ "Neulasta Pre-Filled Syringe - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 15 January 2021. Retrieved 11 October 2021.
  18. ↑ "Neulasta On Body Injector - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 17 January 2021. Retrieved 11 October 2021.
  19. 1 2 3 4 "Neulasta- pegfilgrastim kit Neulasta- pegfilgrastim injection". DailyMed. Archived from the original on 15 July 2021. Retrieved 14 July 2021.
  20. 1 2 "Neulasta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  21. ↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
  22. 1 2 "Drug Approval Package: Neulasta (Pegfilgrastim) NDA #125031". U.S. Food and Drug Administration (FDA). 25 October 2004. Archived from the original on 30 March 2021. Retrieved 11 June 2020.
  23. 1 2 "Pegfilgrastim Monograph for Professionals". Drugs.com. 22 August 2019. Archived from the original on 7 March 2016. Retrieved 11 June 2020.
  24. ↑ Ho, Rodney J. Y.; Gibaldi, Milo, eds. (2004). "Pegfilgrastim". Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons. pp. 157–159. ISBN   978-0-471-45027-6. Archived from the original on 20 October 2021. Retrieved 10 November 2020.
  25. ↑ "Summary for ARTG Entry: 82873 Neulasta pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield" (PDF). Therapeutic Goods Administration (TGA).[ dead link ]
  26. ↑ "NEULASTA pegfilgrastim (Rbe) 6mg/0.6mL injection syringe with automatic needle guard (166387) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  27. ↑ "NEULASTA pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield (82873) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  28. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  29. ↑ Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D, et al. (December 2016). "Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone". Supportive Care in Cancer. 24 (12): 4835–4837. doi:10.1007/s00520-016-3430-9. PMC   5082581 . PMID   27726031.
  30. ↑ Parker SD, King N, Jacobs TF (November 2020). "Pegfilgrastim". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID   30422488. Archived from the original on 20 October 2021. Retrieved 5 November 2020.
  31. 1 2 3 4 "Dyrupeg EPAR". European Medicines Agency (EMA). 30 January 2025. Retrieved 16 February 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.